// App-Quantinova.ai

: Duration of ≥MR4 Is the Best Predictor for a Successful 1st Treatment-Free Remission (TRF1) Attempt in CML Patients Treated with Tyrosine Kinase Inhibitors (TKI); Long-Term Follow-up of a Large Cohort of Patients Including a Cohort Undergoing a 2nd Tfr (TFR2) Attempt

Researchers

Presenter

  • James Anthony Schwarer

Principal Investigators

  • Anthony Schwarer

Medical Centers

  • Department of Haematology, Box Hill Hospital, Box Hill, Australia

  • Monash Health, Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Placental-specific protein 1

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved